Identifier |
20180305_nanos_hottopic1_01 |
Title |
What's New in Graves' Orbitopathy? |
Creator |
Jim Garrity, MD |
Affiliation |
Mayo Clinic, Rochester, MN |
Subject |
Graves' Orbitopathy; Thyroid Eye Disease; Biologic Medications; TSH-receptor; IGF-1 Receptor |
Description |
Graves' orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves' disease (GD). Depending upon the diagnostic criteria used up to 50% of patients with GD have ophthalmic findings; with lid retraction/lid lag being the most common1-3. More severe, sight-threatening disease is seen in approximately 5% of hyperthyroid individuals4. While most GO requires no eye specific treatment,; approximately 15% of GO progress and is of interest to this presentation. |
Date |
2018-04 |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Source |
2018 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS Annual Meeting 2018: Hot Topics:What's New in the Orbit? |
Collection |
Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
Publisher |
North American Neuro-Ophthalmology Society |
Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
Rights Management |
Copyright 2017. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s60p52gd |
Context URL |
The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/ |
Setname |
ehsl_novel_nam |
ID |
1315753 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s60p52gd |